

## **REMARKS**

### Status of the Claims

Claims 1-13, 22, and 23 are pending. Claims 14-21 and 24-30 have been canceled without prejudice or disclaimer of the subject matter claimed therein.

Claim 12 has been amended to correct an inadvertent typographical error.

Claims 22 and 23 have been amended solely for expediting allowance of this application.

Applicants reserve the right to pursue the subject matter deleted from the pending claims or in the deleted claims in one or more divisional and/or continuation applications.

### Objection to Claims

A. Claims 14 and 15 are objected to as substantial duplicates of claim 1.

In the interest of expediting allowance of this application, claims 14 and 15 have been canceled without prejudice or disclaimer of the subject matter claimed therein.

B. Claims 26-30 are objected to as being substantial duplicates of claim 13.

In the interest of expediting allowance of this application, claims 26-30 have been canceled without prejudice or disclaimer of the subject matter claimed therein.

### Rejection of Claims Under 35 U.S.C. § 112, Second Paragraph

Claims 21-30 are rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In the interest of expediting allowance of this application, claims 21 and 26-30 have been canceled without prejudice or disclaimer of the subject matter claimed therein, and claims 22 and 23 have been amended to delete the phrase “such as.” Accordingly, this rejection is not applicable to claims 22 and 23, as they stand.

### Rejection of Claims Under 35 U.S.C. § 112, First Paragraph

Claims 14, 15, and 21-30 are rejected under 35 U.S.C. § 112, first paragraph, as allegedly enabling only for a method of treating rheumatoid arthritis using a pharmaceutical composition

comprising a compound of formula (I) and for a pharmaceutical composition comprising a compound of formula (I) for treating rheumatoid arthritis.

Without acquiescing to the propriety of the rejection and in the interest of expediting allowance of this application, Applicants have deleted claims 14, 15, 21, and 24-30 and amended claims 22 and 23 to overcome the rejection. Accordingly, this rejection is not applicable to claims 22 and 23 as they stand.

#### U.S. Patents and Pending U.S. Applications

Applicants respectfully provide the status of pending U.S. applications with the same assignee that may be considered to be technically related for the Examiner's consideration.

Application	Status
10/507,081	Patent 7,465,728
10/507,162	Patent 7,485,638
10/507,163	Patent 7,446,105
10/507,169	Patent 7,442,697
10/556,561	Patent 7,427,626
10/556,607	Patent 7,579,344
11/769,102	Pending; Ready for Examination
11/769,113	Pending; Ready for Examination
11/793,254	Pending; Ready for Examination
11/817,389	Pending; Ready for Examination
11/995,159	Pending; Ready for Examination
12/088,678	Pending; Ready for Examination
12/088,899	Pending; Ready for Examination
12/089,008	Pending; Ready for Examination
12/302,364	Pending; Preexam Processing
12/302,367	Pending; Ready for Examination
12/304,003	Pending; Preexam Processing

Conclusion

The foregoing amendments and remarks are being made to place the application in condition for allowance. Applicants respectfully request entry of the amendments, reconsideration, and the timely allowance of the pending claims. A favorable action is awaited. Should an interview be helpful to further prosecution of this application, the Examiner is invited to telephone the undersigned.

If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. §1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**

Date: August 28, 2009  
Morgan Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000

By: /Sally Teng/  
Sally P. Teng  
Registration No. 45,397  
Tel. No.: (202) 739-5734  
Fax No.: (202) 739-3001